The assay is designed to detect Group B Streptococcus colonization in pregnant women using vaginal-rectal swab specimens.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The company attributed the increase to gains in its molecular business, including $7.4 million in revenues from Nanosphere, which Luminex acquired in June.
Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests.
The test was designed by diagnostics maker GenArraytion and uses the Luminex xMAP technology.
The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
The M1, a lower-throughput version of the company's Aries System, can process up to six samples and six assays at a time.
Luminex expects Nanosphere to contribute between $13 million and $16 million to its consolidated revenue in 2016.
Luminex's anticipated FY 2016 revenue growth of 6 percent to 9 percent could potentially push higher into the double digits following the integration of Nanosphere.
The CE marking follows the approval of the Aries sample-to-answer system and HSV assay in Europe earlier this year and in the US in late 2015.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.